Data showing the clinical outcomes of Samsung Bioepis’ biosimilar referencing Humira (adalimumab) were shared at the European Congress of Rheumatology’s annual meeting, EULAR 2022.
Samsung Bioepis shared new data from a phase 1 study and a real-world study showing the clinical outcomes associated with its adalimumab biosimilar (Imraldi; Hadlima; SB5), which references Humira, at the EULAR 2022 conference.
EULAR 2022 is the European Congress of Rheumatology’s annual meeting. It is being held in Copenhagen, Denmark, from June 1 through June 4. Imraldi was developed by Samsung Bioepis and Biogen and was approved for use in the European Union in August 2017.
“The addition of new data to our adalimumab biosimilar, SB5, is great news for patients with rheumatic and other inflammatory diseases….Samsung Bioepis has been constantly developing our data package for all our products and we are very pleased to be providing additional evidence which further demonstrates our dedication and commitment to providing quality biologic medicines,” said Donghoon Shin, vice president and medical and lifecycle safety team leader at Samsung Bioepis, in a company statement.
In the randomized, single-blind, 2-arm, parallel group, single-dose phase 1 study, the pharmacokinetics, safety, and tolerability profiles of the new formulation of SB5 (40 mg/0.4 mL) were compared with the original formulation (40 mg/0.8 mL) in healthy male participants. The results demonstrated the clinical equivalence between the 2 formulations.
The PROPER study was a pan-European real-world study sponsored by Biogen. The study was intended to provide insight into the outcomes related to switching from Humira to SB5. Overall, more than 1000 patients with rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, ulcerative colitis, or Crohn disease were enrolled after transitioning to the biosimilar after at least 16 weeks of treatment with the reference product.
Data on the patients were captured for 24 weeks prior to the transition through 48 weeks after switching to SB5. The study demonstrated that the effectiveness of adalimumab therapy remained after 48 weeks on the biosimilar, with most patients choosing to continuing treatment with SB5.
“We are very pleased with the results of the PROPER study which adds to the body of real-world evidence for our biosimilars, offering significant clinical insights for treatment optimization of patients with rheumatoid arthritis….Real-world evidence from studies like PROPER can provide meaningful insights on the use of anti-TNF biosimilars in clinical settings and can advance the understanding of their potential role in managing chronic immune mediated inflammatory diseases,” said Mourad Farouk Rezk, head of Global Medical and Development Biosimilars at Biogen.
SB5 was approved by the FDA in July 2019. When the biosimilar launches on the US market in July 2023, it will be marketed under the name Hadlima and it will be commercialized by Organon. Samsung Bioepis received the approval for a low-concentration formulation and a high-concentration, citrate-free formulation of Hadlima. SB5 was made available to patients in Australia in March 2021.
Samsung Biopeis and Biogen also share European commercialization rights for Benepali (etanercept biosimilar; SB4) and Flixabi (infliximab biosimilar; SB2).
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.